Glycogen limit dextrin

Europe PMC · fetched just now · sorted by publication date

1. 1
   Cardiomyopathy in glycogen storage diseases: diagnosis, prognosis, and advanced management.

   Patel U, Gunes E, Chawla A, Ashman K, Taub A, Arakelyan T, Madani A, Patel K, Bui Q, Adler E. · 2026-07-10

   open access unreviewed
2. 2
   Enhanced lysosomal glycogen breakdown is associated with liver tumorigenesis in glycogen storage disease type III.

   Montalvo-Romeral V, Jauze L, Perrot G, Amaouche M, Gardin A, Aguilar González A, Leblond A, Zitoun-Ardon C, E… · 2025-12-02

   open access unreviewed
3. 3
   Hepatic glycogen storage disease: Deciphering the genotype-phenotype conundrum.

   Samanta A, Ray G. · 2025-09-09

   open access unreviewed
4. 4
   Long-Term Correction of Murine Glycogen Storage Disease Type III by AAV-Mediated Gene Therapy Using an Immunotolerizing Dual Promoter to Express Bacterial Pullulanase.

   Liao KA, Lim JA, Choi SJ, Yi H, Sun B. · 2025-04-17

   cited 1× open access unreviewed
5. 5
   Galectin-3: a novel biomarker of glycogen storage disease type III.

   Rossiaud L, Miagoux Q, Benabides M, Reiss O, Jauze L, Jarrige M, Polvèche H, Malfatti E, Laforêt P, Ronzitti … · 2025-04-14

   cited 4× open access unreviewed
6. 6
   Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.

   Maiorana A, Tagliaferri F, Dionisi-Vici C. · 2023-04-21

   cited 18× open access unreviewed
7. 7
   Suppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice.

   Lim JA, Kishnani PS, Sun B. · 2022-12-08

   cited 13× open access unreviewed
8. 8
   Improvement in hypertrophic cardiomyopathy after using a high-fat, high-protein and low-carbohydrate diet in a non-adherent child with glycogen storage disease type IIIa.

   Kumru Akin B, Ozturk Hismi B, Daly A. · 2022-08-01

   cited 11× open access unreviewed
9. 9
   Diurnal variability of glucose tetrasaccharide (Glc₄) excretion in patients with glycogen storage disease type III.

   Young SP, Khan A, Stefanescu E, Seifts AM, Hijazi G, Austin S, Kishnani PS. · 2020-11-03

   cited 12× open access unreviewed
10. 10
    Involvement of glycogen debranching enzyme in bladder cancer.

    Weinhaus B, Guin S. · 2017-05-09

    cited 4× unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.